SCHEMBL20705352

SCHEMBL20705352

CC(C)(C)OC(=O)C(O)Cn1cccn1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.44
TSHR P16473 2/20 0.42
NLRP3 Q96P20 2/20 0.40
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
PCSK9 Q8NBP7 1/20 0.34
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
ADRB3 P13945 1/20 0.33
THRB P10828 2/20 0.33
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
HTT P42858 1/20 0.32
RORC P51449 1/20 0.31
KCNH2 Q12809 1/20 0.31
LMNA P02545 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26181245 0.87 FDPS (0.35) FDPSTSHRNLRP3PCSK9
SCHEMBL4122055 0.84 FDPS (0.43) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL20713652 0.83 NLRP3 (0.51) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL1712133 0.83 FDPS (0.47) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL1712135 0.83 FDPS (0.47) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL14737322 0.75 FDPS (0.41) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL20263052 0.75 NLRP3 (0.41) FDPSNLRP3HTT
SCHEMBL20263054 0.75 NLRP3 (0.41) FDPSNLRP3HTT
SCHEMBL20708981 0.75 TSHR (0.54) FDPSTSHRNLRP3HDAC1HDAC6
SCHEMBL20514410 0.75 TSHR (0.54) FDPSTSHRNLRP3HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2025-07-10 US disclosed
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NodThera Limited (GB) 2025-03-11 US disclosed
CN-111356680-B Selective inhibitors of NLRP3 inflammasome 诺瑟拉有限公司 2023-11-28 CN disclosed
EP-3661921-B1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NODTHERA LTD (GB) 2023-10-18 EP disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2021-03-25 US disclosed
CN-111356680-A Selective inhibitors of NLRP3inflammasome 诺瑟拉有限公司 2020-06-30 CN disclosed
EP-3661921-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME Nodthera Limited (GB) 2020-06-10 EP disclosed
WO-2019025467-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NodThera Limited (GB) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247011-B2 Selective inhibitors of NLRP3 inflammasome NLRP3, NOD1, NLRP1 FDPS 539/4885TSHR 4688/4885NLRP3 1/4885
US-20250223263-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 FDPS 539/4885TSHR 4688/4885NLRP3 1/4885
US-20210087147-A1 SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, NOD1, NLRP1 FDPS 539/4885TSHR 4688/4885NLRP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.